Brazilian Health Minister’s speech on compulsory licenses exposes a disconnect with the world
Adapted from a story first published by GTPI. Compulsory licensing is a vital public policy tool to combat the high...
World Hepatitis Day 2019: 1.4 million lives lost since last year
Today, 28 July, is World Hepatitis Day 2019. Since the day was marked in 2018, another 1.4 million people have...
Fundación GEP, Argentina, files patent opposition on Hepatitis C treatment
Our partner in Argentina, Fundación GEP (FGEP), has filed an opposition against Gilead’s patent application for the combination, sofosbuvir +...
The people against Gilead. Activists protest at the Brazilian patent office, calling for Gilead’s last sofosbuvir patent application to be rejected
Activists gathered at the Brazilian Patent Office (INPI) in Rio de Janeiro this week, and Gilead’s office in São Paulo....
Collective efforts by civil society groups bar the way to Hepatitis C patents
Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...